J. R. Caton

3.1k total citations · 1 hit paper
15 papers, 1.9k citations indexed

About

J. R. Caton is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, J. R. Caton has authored 15 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in J. R. Caton's work include Body Composition Measurement Techniques (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Cardiovascular and exercise physiology (3 papers). J. R. Caton is often cited by papers focused on Body Composition Measurement Techniques (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Cardiovascular and exercise physiology (3 papers). J. R. Caton collaborates with scholars based in United States, Canada and Russia. J. R. Caton's co-authors include E. David Crawford, Patrick C. McGrath, Nikhil C. Munshi, Scott I. Bearman, Brent A. Blumenstein, Vivek Roy, Robert C. Flanigan, Sydney E. Salmon, P. A. Molé and P. A. Mol and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

J. R. Caton

15 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

2001 1.2k citations Robert C. Flanigan, Sydney E. Salmon et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by J. R. Caton

Since Specialization

Citations

This map shows the geographic impact of J. R. Caton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. R. Caton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. R. Caton more than expected).

Fields of papers citing papers by J. R. Caton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. R. Caton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. R. Caton. The network helps show where J. R. Caton may publish in the future.

Co-authorship network of co-authors of J. R. Caton

This figure shows the co-authorship network connecting the top 25 collaborators of J. R. Caton. A scholar is included among the top collaborators of J. R. Caton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. R. Caton. J. R. Caton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial 2013 ·The Lancet Oncology ·Edward S. Kim, Marcus A. Neubauer, Allen Lee Cohn, Lee S. Schwartzberg, Lawrence Garbo, J. R. Caton, Francisco Robert, Craig H. Reynolds, Terry Katz, (unknown), Lorinda Simms, Scott Saxman	50
2	SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy. 2012 ·Journal of Clinical Oncology ·Edward S. Kim, Marcus A. Neubauer, Allen Lee Cohn, Lee S. Schwartzberg, Lawrence Garbo, J. R. Caton, Francisco Robert, Terry Katz, (unknown), Lorinda Simms, Scott Saxman	3
3	Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer 2011 ·Annals of Oncology ·Guru Sonpavde, В. Б. Матвеев, John M. Burke, J. R. Caton, Mark T. Fleming, Thomas E. Hutson, Matt D. Galsky, William L. Berry, Petr Karlov, Jon Holmlund, Brian Wood, Matthew Brookes, L. Leopold	118
4	A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC) 2011 ·Journal of Clinical Oncology ·Guru Sonpavde, В. Б. Матвеев, John M. Burke, J. R. Caton, Mark T. Fleming, Petr Karlov, Jon Holmlund, Brian Wood, Matthew Brookes, L. Leopold	2
5	Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer 2009 ·Journal of Clinical Oncology ·Craig H. Reynolds, Coleman K. Obasaju, Michael J. Schell, Xueli Li, Zhong Zheng, David Boulware, J. R. Caton, Linda C. DeMarco, Mark Allen O’Rourke, Gail S. Wright, Kristi A. Boehm, Lina Asmar, Jane Bromund, Guangbin Peng, Matthew Monberg, Gerold Bepler	138
6	Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study 2006 ·Clinical Cancer Research ·Anita L. Sabichi, J. Jack Lee, Robert Taylor, Ian M. Thompson, Brian J. Miles, Catherine M. Tangen, Lori M. Minasian, Louis L. Pisters, J. R. Caton, Joseph W. Basler, Seth P. Lerner, David G. Menter, James R. Marshall, E. David Crawford, Scott M. Lippman	34
7	Change in Exercise Tolerance, Activity and Sleep Patterns, and Quality of Life in Patients With Cancer Participating in a Structured Exercise Program 2003 ·Oncology nursing forum ·Stacey Young‐McCaughan, Mary Z. Mays, (unknown), Linda H. Yoder, (unknown), (unknown), J. R. Caton, (unknown), (unknown)	67
8	Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer breakdown → 2001 ·New England Journal of Medicine ·Robert C. Flanigan, Sydney E. Salmon, Brent A. Blumenstein, Scott I. Bearman, Vivek Roy, Patrick C. McGrath, J. R. Caton, Nikhil C. Munshi, E. David Crawford	1223
9	Bidirectional cavopulmonary shunt with an additional source of pulmonary flow: an interim or final stage of palliation 1997 ·Cardiology in the Young ·Ronald W. Day, Charles M. Baker, J. R. Caton, John A. Hawkins, Edwin C. McGough	3
10	Phosphocreatine kinetics in humans during exercise and recovery 1995 ·Medicine & Science in Sports & Exercise ·(unknown), P. A. Mol, J. R. Caton	35
11	Body composition analysis by bioelectrical impedance 1988 ·Medicine & Science in Sports & Exercise ·J. R. Caton, P. A. Mol, William C. Adams, (unknown)	59
12	Body composition analysis by bioelectrical impedance: effect of skin temperature. 1988 ·PubMed ·J. R. Caton, P. A. Molé, W. C. Adams, (unknown)	76
13	Discrepancy in stoichiometry of steady-state muscle [Pi] and [PCr] induced by exercise 1987 ·Journal of Applied Physiology ·J. R. Caton, P. A. Molé, Richard L. Coulson	7
14	THE ASSOCIATIONS AMONG [PCr], [Pi], [ATP], pH AND WORK RATE IN HUMAN SKELETAL MUSCLE 1985 ·Medicine & Science in Sports & Exercise ·J. R. Caton, P. A. Molé, Richard L. Coulson	1
15	In vivo 31P-NMR in human muscle: transient patterns with exercise 1985 ·Journal of Applied Physiology ·P. A. Molé, Richard L. Coulson, J. R. Caton, (unknown), (unknown)	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact